Cutting-edge diagnostics tests covering multiple tumour biomarkers (DNA, RNA and proteins) in solid and liquid biopsies
An up-to-date, comprehensive and proprietary database - OncoKDO - including gene variants information, drugs, clinical trials and scientific literature
An industry-leading bio-IT SaaS integration & interpretation platform for healthcare professionals
Access to our specialised oncology resources (scientific/genomic, clinical and outcomes data experts) and oncologists network.
A tailored and easy to access digital platform combining testing and digital patient/HCP data collection.
"Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions"
The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)